Cell Membrane Predictors of Response to Lithium Prophylaxis of Affective Disorders
Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), D. Kemali, Laura Guida, Pellegrino Biagio Minucci, Bartolomeo Farzati, M. Maj
Cited by 22
Related Papers
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
|The Lancet Oncology|2017|780
Interleukin-12: Biological Properties and Clinical Application
|Clinical Cancer Research|2007|606